EpiCypher was founded in response to the growing demand for high-quality reagents to study chromatin regulation and enable epigenetics-focused drug discovery. The Company is at the forefront of chromatin mapping technologies with the CUTANA® platform for ultra-sensitive genomic profiling assays, including CUT&RUN and CUT&Tag. EpiCypher also offers the largest collection of defined designer nucleosomes (dNucs) on the market along with complementary high-throughput assays and services. EpiCypher is dedicated to bringing these transformative technologies to market and offers superior products and assay services to researchers worldwide.
EpiCypher has launched meCUT&RUN and Multiomic CUT&RUN, two cost-effective tools for high-resolution DNA methylation and multiomic epigenomic profiling.
Explore how emerging in vitro systems — built from primary cells, cocultures, and vascularized tissues — are improving translational research outcomes.